Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory pulmonary disease that causes obstructed airflow from the lungs. Its symptoms include breathing difficulties, coughing, mucus production, and wheezing. People with COPD are at increased risk of developing heart disease, lung cancer, and several other health conditions.
The Chronic Obstructive Pulmonary Disease Treatment (COPD) Market Share is expected to show substantial growth over the forecast period. As per Market Research Future (MRFR) analysis, the market for chronic obstructive pulmonary disease (COPD) was valued at approximately USD 10.7 billion in 2018 and is projected to register 4.2% of CAGR by 2025.
Market Dynamics
The key factor driving the growth of the global market for chronic obstructive pulmonary disease (COPD) market is the growing prevalence of the chronic obstructive pulmonary disease worldwide, which is expected to fuel demand for chronic obstructive pulmonary disease (COPD) drugs. For example, AS per WHO, Global Burden of Disease Study estimates a global prevalence of 251 million cases of COPD in 2016. It is estimated that COPD will become the world's third leading cause of death by 2030. Additionally, the rising geriatric population and increasing customer understanding of the new and innovative treatment options also complement market growth. Through research and development in this field to develop more innovative COPD treatment solutions may also give numerous opportunities for more market growth. However, restrictive government regulations are expected to impede business growth.
Request For Free Sample Copy :
https://www.marketresearchfuture.com/sample_request/1612
Segmentation
The global market for chronic obstructive pulmonary disease (COPD) is segmented into a type of COPD, type of treatment, end-user, and region.
The global demand for chronic obstructive pulmonary disease (COPD) was divided into emphysema and chronic bronchitis, based on type COPD.
The global market for chronic obstructive pulmonary disease (COPD) has been segmented into drugs, surgery, and oxygen therapy, by treatment. The drugs group is further segmented into the bronchodilator monotherapy and anti-inflammatory products. Bronchodilator monotherapy is further sub-segmented into short-acting beta2-agonists (SABAs), long-acting beta2-agonists (LABAs), and anticholinergic agents. The sub-segment of anti-inflammatory drugs is further known as oral & inhaled corticosteroids, and anti-leukotrienes. The surgery segment is sub-segmented into surgery for the reduction of lung volume (LVRS), lung transplantation, bullectomy, and others.
Based on end-users, the global demand for chronic obstructive pulmonary disease (COPD) has been segmented into hospitals and clinics, home care facilities, and others.
Regionally, the global chronic obstructive pulmonary disease (COPD) market is divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. North America is projected to capture a substantial share of the global market for chronic obstructive pulmonary disease (COPD) in the forecast period due to the highly advanced healthcare system and growing cases of chronic obstructive pulmonary disease (COPD) in the region. COPD, for example, is the leading cause of death in the United States, affecting 16 million Americans. Emphysema and chronic bronchitis are the two most severe forms of COPD. More than 8.9 million Americans Reliable Source were diagnosed with chronic bronchitis in 2016, and almost 75% of cases included people over the age of 45.
Europe is projected to be second-largest in the global market for chronic obstructive pulmonary disease (COPD) due to its well-developed market.
The Asia Pacific is projected to be the fastest-growing regional market due to the high number of patients suffering from COPD and the increasing prevalence of respiratory diseases.
The market for chronic obstructive pulmonary disease (COPD) in the Middle East and Africa is projected to rise gradually due to the growth of the healthcare infrastructure.
Browse Complete Toc :
https://www.marketresearchfuture.com/reports/chronic-obstructive-pulmonary-disease-copd-market-1612
Key Players
Abbott Laboratories (US), Almirall (Spain), Astellas Pharma (Japan), AstraZeneca (UK), Boehringer Ingelheim (Germany), Circassia Pharmaceuticals (UK), GlaxoSmithKline (UK), Novartis AG (Switzerland), Pfizer, Inc. (US), and Teva Pharmaceutical Industries Ltd (Israel) are some of the key players operating in the global chronic obstructive pulmonary disease (COPD) market.
Related Reports: Global Anti-Hypertensive Drugs Market Research Report- Forecast to 2022- https://www.marketresearchfuture.com/infographics/anti-hypertensive-drugs-market
NOTE: Our Team of Researchers are Studying Covid19 and its Impact on Various Industry Verticals and Wherever Required We Will be Considering Covid-19 Footprints for a Better Analysis of Markets and Industries. Cordially Get in Touch for More Details.
Chronic Obstructive Pulmonary Disease Treatment (COPD) Market Research Forecast, Regional, Trends and Analysis to 2023
If you’re facing any difficulty performing the troubleshooting steps to fix QuickBooks Error 1612, the article image will guide you in resolving the error.
If you need direct support from experts, you can contact us by dialing our helpline number (844)-932-1139.
When pneumatic or Hydraulic systems produce linear motion, the cylinder becomes an essential component to convert the fluid flow and pressure to velocity and force, respectively.
These days a double-acting hydraulic cylinder is most commonly used.The high force and linear motion that are produced by the cylinders are some of the big reasons why designers specify the pneumatic and hydraulic systems in the very first place.
One of the basic power components of fluids, the cylinders got to evolve into an endless array of sizes, distinctive designs, and configurations.
This versatility doe not only makes a design more-innovative but also makes many application the reality that won’t be practical or possible without any cylinders such as a double-acting hydraulic cylinder.Basics of cylinderThe most common configuration is a double-acting cylinder.
This causes the piston rod to retract.
Simultaneously, the fluid from the opposite side is flown back into the hydraulic reservoir.Note:- If the fluid medium is air, then it is usually vented into the atmosphere.Since the rod-end area of the piston is smaller than the area of the cap-end, the extension force will be much higher than the retraction force (assuming the pressures of equal fluid).
When pneumatic or Hydraulic systems produce linear motion, the cylinder becomes an essential component to convert the fluid flow and pressure to velocity and force, respectively.
These days a double-acting hydraulic cylinder is most commonly used.The high force and linear motion that are produced by the cylinders are some of the big reasons why designers specify the pneumatic and hydraulic systems in the very first place.
One of the basic power components of fluids, the cylinders got to evolve into an endless array of sizes, distinctive designs, and configurations.
This versatility doe not only makes a design more-innovative but also makes many application the reality that won’t be practical or possible without any cylinders such as a double-acting hydraulic cylinder.Basics of cylinderThe most common configuration is a double-acting cylinder.
This causes the piston rod to retract.
Simultaneously, the fluid from the opposite side is flown back into the hydraulic reservoir.Note:- If the fluid medium is air, then it is usually vented into the atmosphere.Since the rod-end area of the piston is smaller than the area of the cap-end, the extension force will be much higher than the retraction force (assuming the pressures of equal fluid).
If you’re facing any difficulty performing the troubleshooting steps to fix QuickBooks Error 1612, the article image will guide you in resolving the error.
If you need direct support from experts, you can contact us by dialing our helpline number (844)-932-1139.